Background: Caspase-6 is a critical factor in neurodegeneration, which is regulated by zinc binding.
SUMMARY
Zinc and caspase-6 have independently been implicated in several neurodegenerative disorders. Depletion of zinc intracellularly leads to apoptosis by an unknown mechanism. Zinc inhibits cysteine proteases including the apoptotic caspases, leading to the hypothesis that zinc-mediated inhibition of caspase-6 might contribute to its regulation in a neurodegenerative context. Using inductively coupled plasma optical emission spectroscopy we observed that caspase-6 binds one zinc per monomer, under the same conditions where the zinc leads to complete loss of enzymatic activity. To understand the molecular details of zinc binding and inhibition, we performed an anomalous diffraction experiment above the zinc edge. The anomalous difference maps showed strong 5 peaks, indicating the presence of one zinc per monomer bound at an exosite distal from the active site. Zinc was not observed bound to the active site. The zinc in the exosite is liganded by K36, E244, and H287 with a water molecule serving as the fourth ligand, forming a distorted tetrahedral ligation sphere. This exosite appears to be unique to caspase-6, as the residues involved in zinc binding are not conserved across the caspase family. Our data suggest that binding of zinc at the exosite is the primary route of inhibition, potentially locking caspase-6 into the inactive helical conformation.
The human caspases are a family of cysteine-aspartic proteases that post-translationally cleave their substrates with high specificity at exposed aspartate residues. Caspases were originally identified for inciting the complex process of apoptotic programmed cell death, but have since been found to play a variety of roles in inflammation, differentiation and development. Apoptotic caspases are categorized as either initiators (upstream, caspase-2, -8, and -9) or executioners (downstream, caspase-3, -6 and -7). Caspase-6 was originally identified as a mammalian ced-3 homologue, MCH-2, an apoptotic gene from human Jurkat T lymphocytes (1) . Caspase-6 differs in several respects from the other executioner caspases. Caspase-6 is much more weakly apoptotic than caspase-3 and -7, although over-expression of caspase-6 does result in apoptosis (2) . Caspase-6 also cleaves a different set of cellular substrates (3, 4) and displays different substrate specificity against peptide substrates (5) . Due to its lower apoptotic potential, caspase-6 has been the subject of less investigation ! ! #! than other caspases, so new insights into caspase-6 physiological roles continue to be uncovered. In the recent past caspase-6 has come into prominence for its role in neurodegeneration. Caspase-6 is expressed in the brain (6) (7) (8) and bordering tissue (9) and cleaves several key targets that are critical in neurodegeneration. Caspase-6 cleaves amyloid precursor protein at position D664 leading to production of the toxic APP-C31 fragment which leads to A -independent neuronal death (10)!), although other caspases may also cleave at this site. Blocking this cleavage is reported to prevent development of the symptoms of Alzheimer's Disease symptoms in a mouse model (11) . Caspase-6 has also been implicated in cleavage of the polyglutamine-expanded huntingtin protein (12). Of the caspases, only caspase-6 is activated by the death receptor 6, resulting in neuronal degeneration (13) . Perhaps the most compelling evidence for the role of caspase-6 in neurodegeneration is the observation that of the caspases, only caspase-6 activation is observed in neuropil threads, neuritic plaques, and neurofibrillary tangles in both sporadic (6) and familial (14) Alzheimer's Disease. Cleavage of tau protein by active caspase-6 appears to be causal in formation of these disease lesions (7) .
Many proteases, including caspase-6, are controlled via zymogen activation, in which proteolytic processing by an upstream protease results in the generation of a cleaved, active protease (for review see (15) ). Caspase zymogens (also called procaspases) are maintained in a fulllength, unprocessed and inactive, dimeric form prior to induction of apoptosis or other activating stimuli. Processing of dimeric zymogens by an upstream caspase removes the prodomain and cleaves the intersubunit linker to form a heterotetramer, which is then active and competent to cleave cellular targets. Cleavage of the intersubunit linker produces two nascent loops that participate in a four-loop substrate-binding groove bundle. In caspase-6 this region is capable of a strand-to-helix transition that results in a unique helical conformation (16) , which can not be attained by any other caspase (17, 18) . Caspase-6 is capable of autoactivation by self cleavage of the intersubunit linker at position 193 following the sequence TEVD (19) . In terms of both zymogen activation and loop control, caspase-6 is distinct from all other caspases.
Due to their cell-death inducing potential, the activities of all apoptotic caspases are tightly regulated. The regulation of each caspase is necessarily unique so that each can perform its independent and non-redundant cellular roles (20, 21) . The most prevalent mechanisms of caspase regulation include zymogen activation, binding of inhibitor of apoptosis protein (IAP) family members, posttranslational modification and metal binding. Amongst the apoptotic caspases, caspase-6 is uniquely resistant to XIAPmediated inhibition at either the active site or the dimer interface (22), underscoring the fact that regulation of caspase-6 is distinctive. To date only caspase-6 has been reported to be inactivated by phosphorylation at S257 by ARK5 kinase (2) , which allosterically prevents the proper conformation of one of the substrate-binding loops (23). The understanding of the unique features of such regulatory pathways improves our ability to utilize caspase-6 as a therapeutic target.
The effect of zinc on caspase-6 has not been explored however the relationship of zinc levels to apoptotic potential has been studied. Extremely high zinc concentrations (>500 M) trigger apoptosis, but at physiologically-relevant concentrations, zinc is a suppressor of apoptosis (24, 25) . Depletion of zinc also leads to apoptosis. Mouse embryos on a zinc deficient diet suffer from neural tube defects, retarded development and apoptotic cell death (26) , likely due to zincmediated caspase inhibition. The inhibition of caspases by transition metals including zinc and copper was reported soon after the discovery of caspases (27) (28) (29) . Exposure of caspases to metal ions alters their cell death potential. In allergic asthma, the loss of airway epithelial zinc was accompanied by changes in the expression of caspase-3 and apoptosis (30, 31) . Treatment of HL-60 cells with zinc chelators increases apoptosis via activation of caspase-3 (32) . The small molecule procaspase-3 activator PAC-1 releases procaspase-3 from zinc-mediated inhibition (33) (34) (35) . The details of caspase-3 zinc-mediated inhibition have not been reported. We have observed that caspase-9 is inhibited by zinc but not by other metals and that caspase-9 binds two zincs per monomer. One zinc binds at the active site and the second zinc binds at an exosite composed of residues C230, H224 and C272 (36) . Together these studies suggest that when the zinc concentration in the cell
is lowered, zinc-mediated inhibition of caspases is relieved and an increase in caspase activation leads to apoptotic cell death. Zinc is an essential element, but is not evenly distributed throughout the body. Mounting evidence suggests that zinc is involved in a variety of neurological diseases (37) . Zinc is found at extremely high concentrations in brain lesions (plaque rim-1,024 M; plaque core-1327 M; senile plaque-1055 M, Alzheimer's neuropil-786 M) (38, 39) . Zinc accumulation in brain is a prominent feature of advanced Alzheimer s Disease and is biochemically linked to the amyloid accumulation and dementia severity. In Alzheimer's Disease patients, zinc concentrations in post mortem brain tissue correlated with the severity of the case, whereas the concentrations of other metals did not differ with severity or relative to control tissues (40) . Intriguingly, these tissues with zinc accumulation are the same tissues in which caspase-6 activation precedes and leads to the formation of neurofibrillary tangles, but does not lead to cell death (41) (42) (43) (44) .
The spatial overlap between zinc buildup and caspase-6 function in neurodegeneration combined with the new molecular details about caspase-9 inhibition by zinc, prompted us to explore the interaction between caspase-6 and zinc as it relates to neurological disorders. In this study we explore the ability of divalent metals to inactivate caspase-6 and uncover the structural mechanism by which caspase-6 metal-binding results in inhibition.
EXPERIMENTAL PROCEDURES

Generation of Caspase-6 Variants
The wild-type caspase-6 constructs consisted of a synthetic gene encoding the E. coli codon-optimized, full-length, carboxy-terminal His 6 -tagged human caspase-6 gene comprising amino acids 1-293 plus His 6 (Celtek Bioscience) ligated into the NdeI/BamHI sites of pET11a vector (Stratagene) or from a constitutive twochain (CT) version of the synthetic caspase-6 gene (16) . Amino acid substitutions were introduced by the Quikchange® site-directed mutagenesis method (Stratagene) in the full-length construct or the constitutive two-chain (CT) construct. All DNA sequences were verified by DNA sequencing.
Caspase-6 Expression and Purification
The caspase-6 expression constructs were transformed into the BL21 (DE3) T7 Express strain of E. coli (New England Biolabs). The cultures were grown in 2xYT media with ampicillin (100 mg/L, Sigma-Aldrich) at 37°C until they reached an optical density at 600 nm of 0.6 (OD 600 = 0.6). The temperature was reduced to 20°C and cells were induced with 1 mM IPTG (Anatrace) to express soluble protein. Cells were harvested after 18 hours of expression to ensure complete processing. Cell pellets were stored at -20°C, freeze-thawed and lysed in a microfluidizer (Microfluidics, Inc.) in a buffer containing 50 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol and 2 mM imidazole. Lysed cells were centrifuged at 18.5K rpm to remove cellular debris. The supernatant was loaded onto a 5 ml HiTrap Niaffinity column (GE Healthcare). The column was washed with a buffer of 50 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol and 50 mM imidazole, and the protein was eluted with the buffer containing 50 mM Tris pH 8.5, 300 mM NaCl, 5% glycerol and 250 mM imidazole. The eluted fraction was diluted by 9-fold into a buffer containing 20 mM Tris pH 8.5 and 2 mM DTT, to reduce the salt concentration. This protein sample was loaded onto a 5 ml Macro-Prep High Q column (Bio-Rad Laboratories, Inc.). The column was developed with a linear NaCl gradient and caspase-6 eluted in a buffer of 20 mM Tris pH 8.5, 120 mM NaCl and 2 mM DTT. The eluted protein was stored in -80°C in the above buffer conditions. The identity of the purified caspase-6 wild-type and variants were analyzed by SDS-PAGE to be 98% pure and ESI-MS was used to confirm mass and purity.
Caspase-3 and -7 Expression and Purification
The caspase-3 full-length human gene in the pET23b vector (Addgene) or the caspase-7 C186A variant (zymogen), made by Quikchange® mutagenesis (Stratagene) of the human caspase-7 gene in pET23b (gift of Guy Salvesen) were transformed into BL21 (DE3) T7 Express strain of E. Coli. Induction of caspase-3 was at 30°C for 3 hours; caspase-7 was at 18°C for 18 hrs. These proteins were purified as described previously for caspase-3 (29) and caspase-7 (45) . The eluted
proteins were stored at -80°C in the buffer in which they were eluted. The identity of purified caspase-3 and -7 were assessed by SDS-PAGE and ESI-MS to confirm mass and purity.
Activity Assays Using Peptide Substrates
For kinetic measurements of caspase activity, 100 nM freshly purified protein was assayed over the course of 15 minutes in a caspase-6 activity buffer containing 100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 20 mM TCEP and 120 mM NaCl. For substrate titrations, a range of 0-500 µM fluorogenic substrate, VEID-AMC, (N-acetyl-Val-Glu-IleAsp-AMC (7-amino-4-methylcoumarin), Enzo Lifesciences) Ex. 365 nm / Em. 495 nm was added to initiate the reaction. Assays were performed in triplicate at 25°C in 100 µL volumes in 96-well microplate format using a Molecular Devices Spectramax M5 spectrophotometer. Initial velocities versus substrate concentration were fit to a rectangular hyperbola using GraphPad Prism (Graphpad Software) to determine kinetic parameters K m and k cat . Enzyme concentrations were determined by active-site titration with the quantitative inhibitor VEID-CHO (N-Acetyl-ValGlu-Ile-Asp-Aldehyde, Enzo Lifesciences). Active-site titrations were incubated over a period of 2 hours in 100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 20 mM TCEP and 120 mM NaCl at nanomolar concentrations of VEID-CHO. Optimal labeling was observed when protein was added to VEID-CHO solvated in DMSO in 96-well V-bottom plates, sealed with tape, and incubated at room temperature in a final volume of 200 µL.
90 µL aliquots were transferred to black-well plates in duplicate, and assayed with 50 fold molar excess of substrate. The protein concentration was determined to be the lowest concentration at which full inhibition was observed. The inhibitory concentrations IC 50 for zinc were determined by performing metal titrations from 0.03 to 450 µM ZnCl 2 in the presence of 20 nM caspase-6 and 300 µM of the fluorogenic substrate VIED-AMC and fitting the data for initial velocity as a function of zinc using equation number 1.
The inhibitory constant K i , was fitted from the same titrations using the Origin software with the equation 2 below using final enzyme and fluorogenic substrate concentrations of 20 nM and 300 µM respectively.
Proteolytic Cleavage of Protein Substrates by Active Caspase-6
To test the ability of various metal cations to inhibit caspase-6 activity we performed proteolytic cleavage assays against full-length procaspases-6 C163S, monitoring cleavage at the intersubunit linker position D193. The full-length procaspase-6 C163S is catalytically inactive and is not capable of self-cleavage at this position, but an active caspase-6 can cleave at the intersubunit linker position D193 and be monitored by assessing migration on a gel. Each metal was tested at 6-fold molar excess incubated for 30 minutes at room temperature. For testing cleavage of full-length procaspase-6 C163S, 1 µM fulllength procaspase-6 C163S was incubated with 1 µM active caspase-6 in caspase-6 assay buffer 100 mM HEPES pH 7.5, 10% sucrose, 0.1% CHAPS, 20 mM TCEP and 120 mM NaCl in a 37°C water bath for 1 hr. Samples were analyzed by 16% SDS-PAGE. The inhibitory concentrations (IC 50 ) for zinc against a natural protein substrate were determined by quantification of the cleavage products in the gel. Gel band quantifications were done by measuring band intensities in a SYGENE BIO IMAGING gel doc with the Gene Tools 6.07 software. The full-length procaspase-6 C163S was set at 100% and quantifications were measured as both the disappearance of the full-length bands and appearance of cleavage bands in the gel.
Zinc Binding Stoichiometry by Inductively Coupled Plasma-Optical Emission Spectroscopy
Purified caspase-6 and variants (10 µM) in 20 mM Tris pH 8.5, 120 mM NaCl, and 20 mM TCEP were incubated with 6 equivalents excess of ZnCl 2 for 30 minutes at room temperature. Unbound zinc was removed by incubating samples of 1.5 mL volume in the presence of
approximately 125 mg of Chelex® 100 for 1 hour, mixing every 15 minutes. A control sample of 1.5 mL of 20 mM Tris pH 8.5, 120 mM NaCl, and 5 mM TCEP buffer was treated in the precisely the same manner to assess the completeness of unbound zinc chelation. Wild-type caspase-6 fulllength samples treated with zinc or untreated were also used as controls for metal content pre and post zinc incubation. Zinc content of the sample supernatant was quantified using a PerkinElmer Optima 4300 DV inductively coupled plasmaoptical emission spectrometer (ICP-OES) equipped with a 40 MHz free-running generator and a segmented-array charge-coupled device (SCD) detector. The sample introduction system consisted of a concentric nebulizer with a cyclonic spray chamber. The concentration of zinc in each sample was determined at 206.2 nm wavelength and converted from ppm to µM to obtain the zinc to monomer of caspase-6 ratio. Post ICP-OES analysis, the remaining samples were tested via absorbance at 280 nm to determine the protein concentration.
Crystallization and Data Collection
Purified Constitutively Two-chain (CT) caspase-6 (!N D179 CT construct lacking both the prodomain and the intersubunit linker, in which the large and small subunits are independently translated from two translational start sites during overexpression (16)) in 20 mM Tris pH 8.5, 2 mM DTT, and 120 mM NaCl was concentrated using Amicon Ultrafree 5K NMWL membrane concentrators (Millipore Inc.) to 6 mg/ml. The crystals grew in 0.1 M Sodium Acetate pH 4.6; 2 M NaCl and 3% ethanol (Hampton Research, HR2-112), in 2-3 days at room temperature in a hanging drop set up. The caspase-6 crystals were soaked for 10 minutes in mother liquor with 10 mM ZnCl 2 , and extensively washed for 10 minutes with cryo-protectant 25% ethylene glycol to remove unbound zinc. The crystals were cryo protected in 25% ethylene glycol and mother liquor and stored in liquid nitrogen. Complete data sets of diffraction images were collected at X6A beamline at Brookhaven National Laboratories National Synchotron Light Source (Upton, NY).
Structure Determination
An x-ray fluorescence scan was carried out to verify the absorption by zinc in the caspase-6 crystals. A clear absorbance peak indicated the presence of zinc and a anomalous diffraction data for zinc-soaked caspase-6 was collected above the zinc absorption edge (1.2861 Å). The zinc-bound caspase-6 crystals diffracted up to 2.8 Å resolution. The data were processed and scaled in HKL2000 in the primitive monoclinic space group P2 1 with CCP4i (46) . The search model successfully used for molecular replacement using Phaser (47) was a dimer of caspase-6 (PDB ID 2WDP, 1.6 Å resolution). To avoid phase bias we omitted the substrate binding loops comprising residues 53-66 (L1 loop), 164-174 (L2), 184-195 (L2'), 211-254 (L3), 257-277 (L4). This solution comprising four monomers in the asymmetric unit was built into the electron density by iterative rounds of model building in Coot (48) and NCS restrained refinement using CCP4i (46) . The structure was refined using automated refinement in Refmac (49) and TLS to a final R/R free of 21.2%/23.3% and was validated by Procheck (50) using CCP4i and Molprobity (51). The final model is PDB ID 4FXO.
RESULTS
Zinc is the Only Transition Metal to Inhibit Caspase-6
A number of caspases including caspase-6 have been reported to be inhibited by zinc (52) , but the effects of other transition metals on caspase-6 function have not been reported. To test the ability of caspase-6 to be inhibited by transition metals we utilized a self-cleavage assay. Whereas a number of caspases autoprocess upon heterologous overexpression in bacteria, only for caspase-6 is a structurally characterized mechanism of autoactivation known (53) . This autoactivation occurs by cleavage of the intersubunit linker at position 193 following the sequence TEVD. The uncleaved caspase-6 zymogen is inactive and cleavage of the intersubunit linker, which generates the two-chain form, is essential for caspase-6 activity (16). The effect of various metal cations on caspase-6 proteolytic activity was assessed by monitoring cleavage of the full-length inactive zymogen (FL C163S, which serves as the substrate), by active, mature caspase-6 ( N D179CT, the enzyme) 1A) . Only zinc but not other metal cations including iron, nickel, cobalt, copper, manganese, potassium, calcium and magnesium was capable of inhibiting caspase-6 (Fig.1B) . This inhibition occurred in a caspase-6 construct that lacks the prodomain and the intersubunit linker, indicating that the inhibition observed occurs in the core domain of caspase-6 and not in the prodomain or intersubunit linker. Caspase-3 shares 33% sequence identity with caspase-6 and has been shown to be sensitive to transition metals like zinc, cupper, cobalt and iron (33, 52) . We were somewhat surprised by the specificity of zinc-mediated inhibition of caspase-6 due to the moderate sequence similarity and reasonably strong structural similarity between these two executioner caspases. To further characterize the inhibitory properties of zinc, we performed kinetic analysis in the presence of increasing concentrations of a real protein substrate (FL C163S) or the fluorogenic tetrapeptide substrate acetyl-valine-glutamateisolucine-aspartate-aminomethylcoumarine (Ac-VEID-AMC). Using a protein substrate, caspase-6 is completely inhibited at 1.5 M zinc (Fig. 1C) with an IC 50 of 0.37 M (Fig.1D) . The result with a fluorogenic tetrapeptide substrate differs, giving an IC 50 for zinc of 3.4 ± 0.5 M and a K i of 0.15 0.04 M (Fig. 1E ) similar to values reported by Salvesen and coworkers (29) , who also used a carbobenzoxy-asp-glu-val-7-amino-4-trifluoromethyl coumarin (Z-DEVD-AFC) fluorogenic tetra-peptide substrate. We note that these differences may be due to the size of the substrates used, as a small tetrapetide (VEID) binds locally only in the active site whereas a protein substrate (299 amino acids) may make contact with other regions of the caspase-6 enzyme (54). Although the K i is in the high nanomolar range, this may in fact be biologically relevant, as the zinc concentration in brain tissue, which is where caspase-6 plays its critical roles in neurodegeneration, can be in the millimolar range (38, 39) .
Caspase-6 Binds One Zinc Per Monomer
We have recently reported two zinc bindings sites on caspase-9 (36), an initiator caspase that shares 31% amino acid identity in the core domain with caspase-6. The caspase-9 zincbinding sites were found using a combination of computational prediction of metal binding sites, site directed mutagenesis and zinc quantification by Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES).
One zinc binds in the caspase-9 active site, coordinated by the catalytic dyad residues C287 and H237 with C239 as a third ligand. The second zinc binds at an exosite composed of H224, C229, C230 and C272. All caspases contain the same catalytic dyad. In caspase-6 E123 is in an appropriate position to serve a third potential zinc ligand in place of C239, which is not present in caspase-6. All but one of the amino acids forming the caspase-9 exosite appear in caspase-6, with the exception of the caspase-9 C230 position which is the non-metal binding residue F114 in caspase-6. Given that three of the four ligands were present in the exosite and three residues are present in the active site, one might predict that like caspase-9, two binding sites would be observed in caspase-6. We were surprised to find that caspase-6 binds just one zinc per monomer (Table 1) , as quantified by ICP-OES.
To interrogate zinc binding at the active site we quantified zinc bound to the C163S version of caspase-6, which lacks the catalytic cysteine that served as a zinc ligand in caspase-9. Zinc binding was unchanged in C163S, indicating that the sole zinc-binding site does not involve the catalytic dyad at the active site. We designed the double mutant H108/C148 to knock out the exosite identified in caspase-9. H108/C148 also retained zinc-binding ability (Table 1) suggesting that zinc does not bind at the exosite homologous to that identified in caspase-9. Thus it appeared that zinc must bind in a site that is unique for caspase-6.
Zinc Binds an Exosite in Caspase-6
Caspase-6 binds just one zinc and that zinc exerts its inhibitory role from a site distinct from the active site or the caspase-9 exosite. To identify the zinc binding site in caspase-6 we determined the structure of caspase-6 using anomalous diffraction at the zinc edge. To introduce zinc, crystals of wild-type caspase-6 were soaked in a solution of 10 mM ZnCl 2 for 10 minutes and then extensively washed with a zinc-free solution. The x-ray absorbance of these crystals was scanned over the range 9600-9700 eV (Fig. 2) . Absorption at the zinc edge (9670 eV) confirmed that zinc had ! ! (! bound to crystallized caspase-6 and was stable to the rigorous washing procedure. X-ray diffraction data were collected above the zinc absorption edge. The structure was solved to 2.83 Å resolution by molecular replacement and refined to R cryst /R free of 21%/23% ( Table 2) . The zinc bound structure shows four monomers or two identical dimers in the asymmetric unit (Fig. 3A) , each dimer representing one functional biological unit composed of two large and two small subunits. Caspase-6 structures in the unliganded, mature (54,67), VEID-bound (17) zymogen (17) and zincbound form all exhibit the same core fold (Fig.  3B ). Caspase-6 is the only caspase known to exist in a latent, highly helical conformation where the 60's and 130's helices are elongated and the 90's helix is rotated out relative to the canonical fold (16, 18) . We soaked zinc into crystals of this helical conformation and found that the zincbound structure remains in the latent, helical form (Fig. 3B) .
Structurally there are several differences near the active site and within the substratebinding loops that are unique to the zinc-bound structure (Fig. 3C, D) . Specifically, within loop L3 several of the amino acids that form the subsites for substrate binding are present in different rotomeric conformations than in the apo-mature form, which we consider to be a natively populated, inactive structure (Fig. 3C) . The cyseine-histidine dyad responsible for peptide bond hydrolysis as well as the L1 and L3 loops are dramatically misaligned in the zinc-bound structure relative to the active, VEID-bound conformation (Fig. 3D) . Activity of a caspase or any enzyme requires that the enzyme bind substrate in the appropriate orientation to facilitate the chemical reaction and that the side-chains involved in catalysis be properly positioned. This misalignment may contribute to the inhibitory effect observed by zinc, but a similar misalignment with different rotomeric conformations has been observed in the apomature structure making it difficult to conclude that of the zinc-binding is entirely responsible for the transition to the inactive conformation.
To unambiguously locate the zinc in the structure, we calculated an anomalous difference electron density map from data collected above the zinc edge. This map showed one strong, 5 peak per monomer, clearly indicating a primary zinc bound at the bottom of the helix that serves as the base of the L4 loop. The amino acids directly involved in zinc binding are K36, E244, H287, with a water molecule serving as the fourth ligand (Fig. 4A) . The ligand composition and distorted tetrahedral coordination geometry suggest that this is a structural zinc. The geometry of the active site, in which the cys-his dyad are 9Å apart (Fig. 4B) , explains why this conformation of the active site is incapable of binding zinc, whereas a properly ordered active site might be capable of ligating zinc.
To test the relevance of the zinc-binding site identified by the anomalous diffraction map, we prepared caspase-6 variants in which the zincbinding residues have been removed. The zinc binding-site variants bound zinc with markedly lower stoichiometry than wild-type. In K36A, E244A, H287A or the double mutant E244A/H287A, zinc binding is ablated ( Table 3) . The fact that substitution of the zinc ligands by alanine ablates zinc binding confirms that the site occupied with zinc in the crystal structure is also the site occupied in solution and measured by ICP-OES.
Zinc Allosterically Inhibits Caspase-6
The fact that the active site of caspase-6 does not bind the inhibitory zinc suggests that the exosite for zinc binding should function as an allosteric inhibitory site. To assess this, we tested the caspase-6 variants, K36, E244A, H287A and E244A/H287A for inhibition by zinc. Surprisingly, these alanine substitutions were not entirely functionally silent. The function of K36A, E244A, H287A or the double mutant E244A/H287A is crippled by 2-, 2-, 14-or 47-fold respectively suggesting that this site is important for activity. Nevertheless, the enzymes retained sufficient activity that we expect the overall fold to be unaltered. Titrations of zinc allowed fitting of the inhibitory properties in caspase-6 variants lacking one or more of the zinc ligands. All of the variants in which the zinc liganding residues are removed have lost a significant amount of sensitivity toward zinc, showing IC 50 values about one order of magnitude weaker than wild-type (Table 3 ). H287 appears to be the primary zinc binding ligand as the alanine mutant H287A shows the worst IC 50 (Table 5) , suggesting these ligands are less critical for zinc binding. Overall, these significant decreases in the inhibitory ability suggest that this caspase-6 exosite is the primary zinc-based inhibitory site and that zinc can allosterically inhibit caspase-6 activity.
Caspase-6 Zinc Exosite is Distinct from the Caspase-9 Exosite.
This caspase-6 allosteric site is the second zinc-binding exosite that we have identified in caspases (Fig. 5A,B) . We recently identified another independent exosite for zinc binding in caspase-9 comprising H224, C229, C230 and C272. The caspase-9 site is non-overlapping with the caspase-6 zinc exosite. Although overall caspases share a high degree of sequence similarity (caspase-6 shares 37, 33, 29 and 28% identity with caspase-3, -7, -8 and -9 respectively), neither of these sites are strictly conserved. The caspase-6 exosite is the most poorly conserved of the binding sites, with only one of the ligands (E244) being conserved. This suggests that this site may be unique to caspase-6. The caspase-9 exosite is somewhat more conserved with three of the four ligands present across the apoptotic caspases. Across the caspase family the most highly conserved zinc-binding site is the active site, which is composed of the conserved catalytic cysteine-histidine dyad (H121 and C163 in caspase-6) and a third strong metal ligand such as D123 for caspase-3, E146 in caspase-7 or E123 in caspase-6.
In both solution and crystals, the dominant zinc binding site for caspase-6 is the exosite. This is likely due to the fact that mature (cleaved) caspase-6 rests in the non-canonical helical conformation as we observe in the zinc-bound structure. In this conformation the active site dyad is not optimally positioned for either catalysis or zinc binding (Fig. 4B) . Nevertheless, we wondered whether comparing the zinc-inhibitory properties of caspase-6 to those of caspase-9 would provide further insight into the mechanistic details of zinc binding and inhibition. The K i for zinc-mediated inhibition of wild-type caspase-6 (0.15 0.04 M) is substantially stronger than any of the mutants in which zinc binding residues are removed (Fig. 5C ). This loss of inhibitory activity suggests that the unique caspase-6 exosite is the primary inhibitory site. Conversely, wild-type caspase-9 has a K i for zinc of 1.5 0.3 M, which does not statistically differ when exosite zinc binding is ablated, as in C272S (Fig. 5C) , establishing the active site as the primary site of inhibition in caspase-9.
Given that the constellation of zincbinding residues in the caspase-6 and caspase-9 active sites are similar, we expect that the K i for zinc-mediated inhibition at the active site of caspase-6 could likewise be of similar magnitude. The magnitude of the K i for zinc in the caspase-6 variants that ablate zinc binding at the exosite is similar to that of caspase-9, which is predominantly inhibited at the active site. This suggests that caspase-6 could potentially be inhibited at the active site with a K i in the range of 3-7 M. Active site inhibition of caspase-6 should only be possible after caspase-6 transitions to the canonical conformation, which occurs in the presence of substrate (16, 19) . It is possible that zinc could potentially act upon caspase-6 in two ways, through a stronger allosteric mechanism at the exosite and through a weaker competitive mechanism at the active site.
Zinc Binds to Both Initiator and Executioner Caspases
Caspase-6 and caspase-9 are both inhibited by zinc, but at different stoichiometries. This led us to interrogate zinc-binding in other caspases. Our findings suggest that each caspase may have its own unique zinc-binding profile. Caspase-3 binds three zinc per monomer and caspase-7 binds just one zinc per monomer (Table  4) . A priori it is tempting to speculate that caspase-7 may bind the single zinc at the active site since it cannot attain the helical conformation that we see in caspase-6 (17) . It is difficult to predict the zincbinding locations in caspase-3. It seems likely that the active site is one of the three caspase-3 zincbindings sites. Since neither the caspase-9 nor the caspase-6 exosite is conserved in caspase-3 ( significance, similar to the site we have identified in caspase-6.
Discussion
Due to their critical roles in irreversible processes like apoptosis, inflammation and neurodegeneration, caspases are highly regulated proteins. It is becoming clear that each caspase is subject to a unique combination of activating and inhibitory processes including upstream zymogen activation (mediated by an initiator caspase as part of a large multi component complex such as the DISC or apoptosome), phosphorylation, and other post-translational modifications. Caspase-6 differs from other family members in that it is not subject to inhibition by IAP proteins and can autoactivate under certain conditions. We have shown that caspase-6 can be inhibited by zinc allosterically. The underlying physiological reason as to why caspases evolved to bind zinc is not entirely clear but we speculate that the native affinity of a cysteine-histidine dyad requires an appropriate response in a zinc-rich environment. Caspase-6, in particular, is known to play a role in cells and tissues with extremely high zinc concentrations (39, 55) , so perhaps it was essential that caspase-6 evolve mechanisms to respond to these conditions. Beyond this, why caspase-6 should be subject to allosteric inhibition by zinc remains somewhat unclear. One possible explanation is that zinc can allosterically inhibit caspase-6 regardless of its structural state: zymogen, helical conformation or mature canonical conformation and is thus a global means of caspase-6 inhibition.
Caspase-6 is inhibited by zinc but not by other cationic metals. This is somewhat unusual, given the relative similarity in size and charge of zinc and many other transition metal cations. The coordination sphere in the caspase-6 inhibitory site is composed of K36, E244, H287 and a water molecule, in a distorted tetrahedral geometry. Glutamate and histidine are common ligands for cations. Coordination of zinc by lysine is not common, but is not unheard of, as it has been observed in 1% of structural zinc binding sites in proteins deposited in the Protein Data Bank (56-61). Whereas lysine can coordinate zinc, it has not been observed to coordinate other metals. For example, in the type I copper binding protein amicyanin, the mutation of one of the copper ligands, methionine, to lysine converted the enzyme from copper binding to selectively zinc binding, demonstrating the specificity of lysine as a zinc ligand (62). Thus the specificity of caspase-6 for inhibition by zinc may be the result of the rare ligand, K36, participating in the coordination sphere.
The caspase-6 zinc-binding exosite is distal from the active site and is capable of leading to enzymatic inhibition, categorizing it as an allosteric site. Allosteric regulation is traditionally viewed as a binding event at one site that indirectly affects the activity at another via inducing a number of linked conformational changes in the protein. Caspases seem to be ripe for allosteric regulation, likely because of the extreme plasticity of the loops that compose the active site groove. We have previously observed how phosphorylation of caspase-6 at S257 results in a steric clash of as few as three atoms in the sidechain of P201, which leads to allosteric inhibition by preventing the active conformation of one loop. In caspase-7 (45,63,64) or -1 (65, 66) binding small synthetic allosteric inhibitors at the dimer interface leads to a series of sidechain conformational changes that ultimately blocks the substrate-binding groove, preventing proteolytic activity. These examples and a great number of other examples from a large number of proteins are satisfying as it is possible to visualize the series of sidechain conformational changes that lead to inactivation. In this structure of zinc-bound caspase-6, we cannot trace a chain of discrete conformational changes in adjacent side chains that lead to inactivation.
A second class of allosteric regulators of enzymes modulate the thermodynamic equilibrium of various folded states that leads to disruption of the enzymatic properties without causing obvious changes along a pathway of side chains linking the allosteric and active sites. Examples of this class include peptide inhibitors of factor VIIa (67, 68) and small-molecules inhibitors of -lactamase (69). Very recently a novel allosteric peptide, pep419, which binds near the 90's helix in caspase-6 inducing a tetrameric state has been reported to function via this second class of allosteric mechanism. The authors state "The effect of pep419 is not the transmission of a specific conformational change from the peptide binding site to the active site but rather a more global effect on protein dynamics whereby peptide
binding induces tetramerization and, most likely, a structural rigidity that prevents catalytic turnover." (70) . Of course in both classes of allosteric inhibition, the same fundamental thermodynamic properties control the equilibrium and it is simply the ability to visualize these pathways that differs between the two classes. We posit that zinc falls into this second class of allosteric modulators, locking caspase-6 into the inactive helical conformation by altering the equilibrium ensemble in both the absence and presence of substrate (Fig. 6 ).
We were surprised to observe that substitution of one of the residues in the caspase-6 zinc-binding exosite, E244, had such deleterious effects on enzymatic function. This significant loss in activity may suggest that E244 sits in a sensitive site and leads us to speculate about the role of this site. Only one exosite for substrate binding has been identified in any caspase. In caspase-7 a tetra lysine sequence at residue 38 ( 38 KKKK) is critical for caspase-7 to bind and distinguish protein substrates (54) . K36, is near the location of the caspase-7 exosite, is close to the N-terminus of caspase-6 and is one of the first residues to be crystallographically ordered following the disordered prodomain, leading us to ponder whether this zinc-binding site may be involved in regulating substrate recognition. The fact that the K i for zinc is stronger for protein substrates than for peptide substrates (Fig. 1B-E) further supports this idea.
Although E244A is an isolated mutation, it may be worthwhile to note that many mysteries about the regulation of caspase-6 remain, including the role of the prodomain and its interaction with other regions of caspase-6. E244 is not involved in any obvious interactions in any caspase-6 structure that would lead to loss of function. Thus further examination of this mutation may provide new insights into caspase-6 activity. In the caspase family, only caspase-6 can transition between a canonical and a helical conformation (16) . There have been differing opinions about the relevance of this helical conformation (18, 71) . We have observed a spectroscopic signature that indicates that caspase-6 is helical in solution at neutral pH in the absence of substrate, and is converted to the helical conformation upon binding substrate (16) . The active site of caspase-6 presents a constellation of ligands that should be well-suited to bind zinc when they are properly positioned for catalysis, as occurs in the canonical conformation. We have shown that deleting the active site zinc-binding ligands has no effect on zinc binding ability, implicating the caspase-6 exosite is the primary zinc-binding and inhibitory site. At the same time, this result provides insight into the solution-based conformation of caspase-6. The fact that caspase-6 does not principally bind zinc in the active site, as does caspase-9, suggests that the active site in solution is not competent for zinc binding. The most likely explanation for this is that caspase-6 exists in the helical conformation in solution so the catalytic cysteine-histidine dyad are far apart from one another and therefore cannot bind zinc at the active site. Thus these data provide a second piece of evidence that caspase-6 exists in the helical conformation in solution in the absence of substrate, which may make the helical conformation an attractive target for inhibitor design. To test metal inhibition in an electrophoretic mobility gel-based assay, caspase-6 fragments produced from active caspase-6 (N D179 CT) mediated cleavage of the full-length C163S zymogen which serves as the substrate. Fragments from cleavage include: full length (FL), FL lacking the N-terminal prodomain ( N-FL), Large (Lg) and Small subunits (Sm) with the amino acids present in those bands (subscripts) labeled. (C) Zinc is the only metal cation that inhibits caspase-6 activity. Caspase-6-mediated cleavage of caspase-6 FL C163S zymogen tested at various zinc concentrations in an electrophoretic mobility gel based assay as caspase-6 fragments produced from active caspase-6-mediated cleavage at the intersubunit linker. Proteolytic fragments are labeled as in (B). (D) In-gel IC 50 band quantification measuring band intensities. The full-length procaspase-6 FL C163S was set as 100% (uncleaved). Band quantification was measured as disappearance of these bands and appearance of cleavage bands in the gel. 50% band intensity when the disappearance of FL C163S and appearance of the large subunit D193 cross was set as ! ! the in gel IC 50 for zinc inhibition of 0.37 M. (E) Dose response inhibition of caspase-6 in the presence of zinc and a fluorogenic substrate (Ac-VEID-AMC). IC 50 was fit from independent duplicate metal titration on three independent days. (purple), clearly indicating the location of zinc. The sidechains and water serving as ligands are drawn as sticks. The 2F o -F c electron density map (blue) into which the structure was build is contoured at 1 . (B) Caspase-6 dimer. The boxed regions shows active site, which contains residues appropriate for metal binding including H121, E126 and C163. In this structure these residues are not properly positioned to coordinate zinc. The caspase-6 zincbinding exosite is shown with in the sidechain ligands for zinc in sticks, zinc (blue) and the water molecule (red). A structure-based sequence alignment of the apoptotic human caspases in the regions of the zinc binding sites. The active site is conserved but the caspase-6 or -9 exosites are not conserved across the apoptotic caspases. Alignments were performed structurally and residues are numbered according to the numbering of each individual caspase. The presence of insertions and deletions in the sequences of various caspases explains why the intervals between the sites differ. (B) Caspase-6 in the canonical conformation shows the active site and zinc-binding exosites circled. Zinc-binding ligands are in sticks and the zincs are shown as gray spheres. The caspase-6 zinc-binding site is shown as in the crystal structure. The zinc-bound conformations of the active site and the caspase-9 exosites were modeled by selecting a new, plausible rotomeric conformations for the zinc-liganding side chains and modeling a zinc molecule with proper distance for zinc binding. (C) The K i for wild-type caspase-6 inhibition by zinc is much stronger than caspase-6 variants in which the zinc-ligands are deleted, suggesting ! ! that the exosite is the primary inhibitory site for zinc. This is in contrast with caspase-9, in which there is no statistical difference in the activity when the caspase-9 exosite is ablated by the C272S substitution. Figure 6 . Model for the Mechanism of Caspase-6 Inhibition by Zinc. Caspase-6 exists in equilibrium between the helical conformation and the canonical conformation. Prior to substrate binding the equilibrium strongly favors the helical conformation. In order to bind substrate caspase-6 has to reorder the ends of two elongated helices into the strands or loops observed in the canonical form and compatible with substrate binding. In the presence of zinc, the helical form of caspase-6 binds only one zinc per monomer at the exosite and is allosterically inhibited at this exosite. In the helical conformation the active site does not bind zinc due to the disorganization of the active site residues, which are also favorable zinc liganding residues. When caspase-6 is in the canonical conformation, zinc can also bind at the active site so that two zinc per monomer bind and inhibit caspase-6. 
